Department of Spinal Cord Injury, SARAH Rehabilitation Hospital Network/SARAH Brasilia, Brasília, Brazil.
Laboratory of Respiratory Physiology, University of Brasília, Brasília, Brazil.
Spinal Cord. 2019 Oct;57(10):890-896. doi: 10.1038/s41393-019-0293-1. Epub 2019 May 17.
Retrospective cohort study.
To compare the cost and incidence of venous thromboembolism (VTE) and bleeding between two different VTE pharmacological prophylaxis strategies in individuals with spinal cord injury: one based on motor impairment (Protocol 1) and the other based on time from the lesion and presence of associated risk factors for VTE (Protocol 2).
A tertiary rehabilitation hospital in Brazil.
We retrospectively reviewed a total of 1475 charts of individual admissions: 814 individuals received pharmacological prophylaxis according to Protocol 1 and 661 according to protocol 2. These cohorts were compared with respect to age, time and level of injury, length of stay, AIS classification, type of injury, and occurrence of VTE and major bleeding. The number of prescribed doses of enoxaparin and expenditures associated with enoxaparin during each period were evaluated.
The median lesion time was 3 years. The risk-based strategy drastically reduced the average monthly use of enoxaparin by 75% and the 12-month enoxaparin expenditure by $119,930.33, without increasing the risk of VTE. The incidence density of thromboembolic events was 0.55/10,000 patient-days, and all events occurred in individuals receiving prophylaxis according to Protocol 1.
Time from injury and risk of VTE-based protocol for indication of pharmacological prophylaxis drastically reduced costs. No difference in occurrence of VTE was observed.
回顾性队列研究。
比较两种不同的脊髓损伤患者静脉血栓栓塞症(VTE)药物预防策略的成本和 VTE 发生率和出血率:一种基于运动功能障碍(方案 1),另一种基于损伤时间和 VTE 相关危险因素的存在(方案 2)。
巴西的一家三级康复医院。
我们回顾性分析了总共 1475 份个人住院病历:814 名患者根据方案 1 接受药物预防,661 名患者根据方案 2 接受药物预防。比较了这两个队列的年龄、损伤时间和水平、住院时间、AIS 分类、损伤类型以及 VTE 和大出血的发生情况。评估了每个时期依诺肝素的规定剂量数和与依诺肝素相关的支出。
中位损伤时间为 3 年。基于风险的策略将依诺肝素的平均每月使用量大幅减少了 75%,12 个月的依诺肝素支出减少了 119930.33 美元,而 VTE 的风险并未增加。血栓栓塞事件的发生率密度为 0.55/10000 患者天,所有事件均发生在接受方案 1 预防的患者中。
基于损伤时间和 VTE 风险的药物预防方案的指示大大降低了成本。未观察到 VTE 发生的差异。